Boehringer Ingelheim Reports the Acquisition of Nerio Therapeutics for $1.3B
Shots:
- Boehringer Ingelheim has acquired Nerio Therapeutics for up to $1.3B, to strengthen its immuno-oncology pipeline
- The acquisition adds Nerio Therapeutics’ preclinical program to Boehringer Ingelheim. The company will further develop the program to treat cancer patients
- Nerio’s small molecules target the protein tyrosine phosphatases N1 and N2 (PTPN1 & PTPN2), which can activate the immune system to combat cancer cells
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
